Fundraising FoxThird Rock Ventures — 2019 Investments
6 investments dated 2019 · listed companies and verified rows first · show all
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Strateos develops remote access laboratory software and automation platforms that enable scientists to design, execute, and analyze experiments through cloud-based robotics and control systems.
AI & Machine LearningBiotechDeep TechRoboticsSaaSMenlo Park, US
Chris Krueger(Executive Officer)inMark Fischer-Colbrie(Executive Officer, Director)inDavid Lynch, PhD(Chief Executive Officer)Marc Siladi(Chief Operating Officer)in
BoardJoshua Wolfe(Director)Armen Vidian(Director)in
Co-investorsDCVC (Data Collective)Lux CapitalBlueStone Venture PartnersAlumni VenturesDolby Family VenturesHarmonix Fund+6 more
BiotechChestnut Hill, US
Joseph Italiano(Director)inJonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)
Board seatPhilip Reilly· per SEC Form D · $26.4M raise · filed Aug 2019
Co-investorsBoston Harbor AngelsQiming HealthcareVivo Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cardurion Pharmaceuticals, Inc.Hookipa PharmaThrive Earlier Detection
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.